LRMR
NASDAQLarimar Therapeutics Inc.
Price$4.06-0.24 (-5.58%)
01:30 PM07:45 PM
News · 26 weeks36-20%
2025-11-022026-04-26
Mix2390d
- SEC Filings9(39%)
- Other7(30%)
- Insider4(17%)
- Offering3(13%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
- PRLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaBALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled "Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling" in the journal Clinical and Translational Science, an official peer-reviewed publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). The article is now available online (link). Nonclinical data across mice, rats, and non-human primates consistently showed that treatm
- SECSEC Form DEF 14A filed by Larimar Therapeutics Inc.DEF 14A - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form PRE 14A filed by Larimar Therapeutics Inc.PRE 14A - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form S-8 filed by Larimar Therapeutics Inc.S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form 10-K filed by Larimar Therapeutics Inc.10-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsBreakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchBALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL. Presentation details can be found below. Leerink Partners Global Healthcare ConferenceDate: Tuesday, March 10, 2026Time: 8:40 AM ETWebcast Link:https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/FAcSQYGbUgaSReiyPwMwXA The Citizens Life Sciences ConferenceDate: Wednesday, March 11, 2026Tim
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Larimar Therapeutics Inc.SCHEDULE 13D/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
- INSIDER* Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERDirector Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERDirector Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERDirector Sherman Jeffrey W bought $25,000 worth of shares (5,000 units at $5.00) (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- SECSEC Form 424B5 filed by Larimar Therapeutics Inc.424B5 - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingBALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $5.00 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering
- SECSEC Form 424B5 filed by Larimar Therapeutics Inc.424B5 - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingBALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All s
- PRBiotech and Big Tech Drive the Morning NarrativeDENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today's developments are shaping a compelling growth narrative. KBLB) featured on Cover of March 2026 National Geographic" height="600" src="https://ml.globenewswire.com/Resource/Download/c66bcdc7-5761-4898-a027-43978e0ac618/kblb-national-geographic-march-2026-newsstand-cover-art.jpg" width="413" data-dpi="300" data-caption="Kraig Biocraft Laboratories (OTCQB:KBLB) featured on Cover of March 2026 National Geographic" data-filename="KBLB
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyFDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission seeking accelerated approvalTopline open label study data to support BLA submission expected in Q2 2026 Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved BALA CYNWYD, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
- INSIDERChief Development Officer Shankar Gopi was granted 25,637 shares, increasing direct ownership by 50% to 76,443 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERChief Medical Officer Clayton Russell was granted 25,637 shares, increasing direct ownership by 56% to 71,443 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
LRMR FAQ
7 questionsWhat does Larimar Therapeutics Inc. do?
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.Where does LRMR stock trade?
Larimar Therapeutics Inc. (LRMR) is listed on NASDAQ.What sector and industry is LRMR in?
Larimar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Larimar Therapeutics Inc. go public?
Larimar Therapeutics Inc. (LRMR) completed its IPO in 2014.What are analysts saying about LRMR?
Larimar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $1800.00 price target on 2025-01-29.What companies are similar to LRMR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare LRMR side-by-side with any of them on Quantisnow.How can I track LRMR on Quantisnow?
Quantisnow aggregates Larimar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LRMR to receive live email and push alerts on every new disclosure.